Plant Health Care plc fell short of revenue expectations in 2019, due to adverse market conditions in the US and delays to sales in Brazil. As a result, sales of Harpin aß by the Group were down 34% compared to the prior year. These factors obscured positive customer benefits in newly launched Harpin aß products, supported by new relationships with very strong national distributors in the US and Brazil. These have established a very promising base for revenue growth in 2020 and beyond.

The Board's "severe downside" forecast is based on sales that are further constrained in Mexico and Europe for the rest of 2020. Sales in the USA are not affected. Sales to Brazil fall to 25%, compared with earlier forecast. In addition to the impact of reduced sales, it assumes that $1.0 million in Accounts Receivable due in 2020 will not be collected until 2021. In this scenario, sales projections in 2021 are lower than previously forecast.